UPDATE: Morgan Stanley Raises PT On Edwards Lifesciences Corp., Say Upside Now Tied To Bull Case

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on

, and raised the price target from $120.00 to $130.00. In the report, Morgan Stanley noted, “Guidance for 2015 was consistent with Street models, but recent TAVR strength suggests upside is likely. Sapien 3 is not included in 2015 guidance and based on expedited MDT reviews will likely prove conservative. Our Bull case is $175 but requires loftier assumptions a few years out.” Edwards Lifesciences Corp. closed on Monday at $132.13.